Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057575 · ClinicalTrials.gov registry record · Phase 2
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 298
- Enrollment target
NCT02057575 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 298 participants.
The verdict
NCT02057575, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 298 participants
- Enrollment target
Study Summary
To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
Interventions
- DRUG PG324 Ophthalmic Solution 0.01%
- DRUG PG324 Ophthalmic Solution 0.02%
- DRUG Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- DRUG Latanoprost Ophthalmic Solution 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057575
The ClinicalTrials.gov registry entry for NCT02057575 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PG324 Ophthalmic Solution 0.01% is the first listed.
NCT02057575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057575 about?
NCT02057575 is a clinical study titled "Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure". To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
What is the current status of trial NCT02057575?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2014-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02057575?
The interventions under investigation include: PG324 Ophthalmic Solution 0.01% (DRUG), PG324 Ophthalmic Solution 0.02% (DRUG), Netarsudil (AR-13324) Ophthalmic Solution 0.02% (DRUG), Latanoprost Ophthalmic Solution 0.005% (DRUG).
Who is sponsoring clinical trial NCT02057575?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.